EPIRUS Biopharma (EPRS) Misses Q4 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to EPIRUS Biopharma (EPRS) Misses Q4 EPS by 7c

EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update

March 15, 2016 6:00 AM EDT

BOSTON, March 15, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS), a pure-play biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today reported financial results for the fourth quarter and fiscal year of 2015, and provided a business update.

During 2015, we made significant progress on our strategy of efficiently developing high quality biosimilars that will allow more people... More